Prudence Ive to Anti-Retroviral Agents
This is a "connection" page, showing publications Prudence Ive has written about Anti-Retroviral Agents.
Connection Strength
0,602
-
Previous antiretroviral drug use compromises standard first-line HIV therapy and is mediated through drug-resistance. Sci Rep. 2018 10 25; 8(1):15751.
Score: 0,114
-
Suboptimal immune recovery during antiretroviral therapy with sustained HIV suppression in sub-Saharan Africa. AIDS. 2018 05 15; 32(8):1043-1051.
Score: 0,110
-
Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity, and implications for HIV-TB programs. J Acquir Immune Defic Syndr. 2014 Apr 01; 65(4):423-8.
Score: 0,083
-
Early warning indicators for population-based monitoring of HIV drug resistance in 6 African countries. Clin Infect Dis. 2012 May; 54 Suppl 4:S294-9.
Score: 0,073
-
Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. Clin Infect Dis. 2012 Jun; 54(11):1660-9.
Score: 0,072
-
Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011 Oct 20; 365(16):1482-91.
Score: 0,070
-
Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet. 2010 Jul 03; 376(9734):33-40.
Score: 0,064
-
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis. 2010 Mar 15; 201(6):803-13.
Score: 0,016